# Bevacizumab in Advanced Hepatocellular Carcinoma

> **NCT00162669** · PHASE2 · UNKNOWN · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 50 (—)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** bevacizumab

## Key facts

- **NCT ID:** NCT00162669
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 50 (—)
- **Last updated:** 2006-09-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00162669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00162669, "Bevacizumab in Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00162669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*